SAB Biotherapeutics (SABS) Price & Analysis

Compare

153 Followers

SABS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.00 - $6.60

Previous CloseN/A

Volume58.44K

Average Volume (3M)2.90M

Market Cap

$22.90M

Enterprise Value$17.02M

Total Cash (Recent Filing)$12.85M

Total Debt (Recent Filing)$6.78M

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.09

Shares Outstanding10,411,061

10 Day Avg. Volume190,188

30 Day Avg. Volume2,904,120

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.74

Enterprise Value/Revenue45.04

Enterprise Value/Gross Profit-11.90

Enterprise Value/Ebitda-0.56

Forecast

1Y Price Target

$8.40

Price Target Upside315.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentSAB-142's encouraging Phase 1 safety and efficacy in healthy volunteers sets the stage for Phase 2b looking to modulate type 1 diabetes progression.

Investor ConfidenceParticipation from strategic investor Sanofi and new noteworthy investors like RA Capital and Blackstone Multi-Asset Investing highlights strong investor confidence.

Regulatory ApprovalThe Phase 2b SAFEGUARD trial is confirmed by the FDA to serve as a pivotal trial for FDA approval.

Bears Say

Adverse EventsSAB-142 was generally well tolerated among healthy volunteers, with most adverse events being mild and resolving quickly, and no drug-related serious adverse events reported.

Market CompetitionSAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab, which could be advantageous for outpatient settings.

SAB Biotherapeutics News

SAB Biotherapeutics price target lowered to $12 from $20 at Chardan

Chardan lowered the firm’s price target on SAB Biotherapeutics (SABS) to $12 from $20 and keeps a Buy...

5d ago

SABS

SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year

Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We are extremely pleased to have recently raised...

6d ago

SABS

SAB Biotherapeutics announces oversubscribed $175M private placement

SAB BIO entered into a securities purchase agreement with certain accredited and institutional investors to raise $175M upfront...

23d ago

SABS

SAB Biotherapeutics Reports Increased Losses Amid Funding Boost

Sab Biotherapeutics, Inc. ( ($SABS) ) has released its Q2 earnings. Here is a breakdown of the information...

5d ago

SABS

SAB Biotherapeutics Secures $175M Funding, Paving Way for Phase 2b Diabetes Trial and Justifying Buy Rating

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on SAB Biotherapeutics. The associated price target...

5d ago

SABS

SAB Biotherapeutics Secures $175M Investment, Strengthening Financial Position and Advancing Type 1 Diabetes Treatment

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics and decreased the price target...

22d ago

SABS

SAB Biotherapeutics Secures $175M in Private Placement

SAB Biotherapeutics ( ($SABS) ) just unveiled an update. On July 21, 2025, SAB Biotherapeutics announced an oversubscribed...

23d ago

SABS

SAB Biotherapeutics Holds Annual Stockholders Meeting

An update from SAB Biotherapeutics ( ($SABS) ) is now available. On July 17, 2025, SAB Biotherapeutics, Inc....

26d ago

SABS

SAB Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of SAB Biotherapeutics (SABS) with a Buy rating and $10 price target Following a...

3M ago

SABS

SAB Biotherapeutics reports Q1 net loss $5.2M vs $5M last year

SAB BIO held cash and equivalents of $12.9 million as of March 31, 2025, compared to $20.8 million...

3M ago

SABS

SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy

Sab Biotherapeutics, Inc. ( ($SABS) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

SABS

SAB Biotherapeutics price target lowered to $20 from $25 at Chardan

Chardan analyst Keay Nakae lowered the firm’s price target on SAB Biotherapeutics (SABS) to $20 from $25 and...

4M ago

SABS

Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating

Analyst Edward White of H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report), retaining...

4M ago

SABS

SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024

SAB Biotherapeutics (SABS) held cash and equivalents of $20.8 million at December 31, 2024, compared to $56.6 million...

4M ago

SABS

SABS FAQ

What was SAB Biotherapeutics’s price range in the past 12 months?

SAB Biotherapeutics lowest stock price was $1.00 and its highest was $6.60 in the past 12 months.

What is SAB Biotherapeutics’s market cap?

SAB Biotherapeutics’s market cap is $22.90M.

When is SAB Biotherapeutics’s upcoming earnings report date?

SAB Biotherapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 97 days.

How were SAB Biotherapeutics’s earnings last quarter?

SAB Biotherapeutics released its earnings results on Aug 07, 2025. The company reported -$1.088 earnings per share for the quarter, beating the consensus estimate of -$1.092 by $0.004.

Is SAB Biotherapeutics overvalued?

According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SAB Biotherapeutics pay dividends?

SAB Biotherapeutics does not currently pay dividends.

What is SAB Biotherapeutics’s EPS estimate?

SAB Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SAB Biotherapeutics have?

SAB Biotherapeutics has 10,411,061 shares outstanding.

What happened to SAB Biotherapeutics’s price movement after its last earnings report?

SAB Biotherapeutics reported an EPS of -$1.088 in its last earnings report, beating expectations of -$1.092. Following the earnings report the stock price went up 1.826%.

Which hedge fund is a major shareholder of SAB Biotherapeutics?

Currently, no hedge funds are holding shares in SABS

SAB Biotherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-127.48%

Trailing 12-Months

Asset Growth

-51.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SAB Biotherapeutics (SABS) Earnings & Revenues

Historic Earnings Reports

SABS Stock 12 Month Forecast

Average Price Target

$8.40

▲(315.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.23,3.1353846153846154,4.0407692307692304,4.946153846153846,5.851538461538461,6.756923076923076,7.662307692307692,8.567692307692308,9.473076923076922,10.378461538461538,11.283846153846154,12.18923076923077,13.094615384615384,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.23,2.7046153846153844,3.1792307692307693,3.6538461538461537,4.128461538461538,4.603076923076923,5.077692307692308,5.552307692307693,6.026923076923077,6.501538461538461,6.976153846153846,7.450769230769231,7.9253846153846155,{"y":8.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.23,2.212307692307692,2.1946153846153846,2.1769230769230767,2.1592307692307693,2.1415384615384614,2.123846153846154,2.106153846153846,2.0884615384615386,2.0707692307692307,2.0530769230769232,2.0353846153846153,2.0176923076923075,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.1,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >